Loading...
•
Dec 31, 2020
Exact Sciences Q4 2020 Earnings Report
Exact Sciences reported strong Q4 2020 results, driven by its screening and precision oncology segments, despite challenges posed by the pandemic.
Key Takeaways
Exact Sciences Corp. announced Q4 2020 revenue of $466.3 million and full year revenue of $1,491.4 million. The company's performance was driven by its Cologuard and Oncotype tests. The company reported a net loss of $(436.8) million, or $(2.79) per share, and adjusted EBITDA of $87.9 million.
Total revenue for Q4 2020 was $466.3 million.
Screening revenue increased to $249.7 million, a 9% increase year-over-year.
Precision Oncology revenue was $117.6 million.
COVID-19 testing revenue was $99.1 million.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
The company did not provide specific forward guidance in this earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income